Human Liver Organoids as a New Model for Non-Alcoholic Fatty Liver Disease

by Karen O'Hanlon Cohrt | Jul 18, 2023 | Disease Models

The lack of approved treatments for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatosis (NASH) is largely explained by the shortcomings of cellular models used to unravel disease mechanisms, identify and validate new drug targets, and screen...

NASH – The Urgent Need for Better Disease Models and New Therapies

by Karen O'Hanlon Cohrt | Apr 4, 2023 | Disease Models

This article was originally published on 4th April 2023. It was revised and republished on 19th March 2023, to reflect important updates in the NASH therapeutic development space, including FDA approval of Rezdiffra in March 2024. Welcome to our new mini-series about...

Better Blood Brain Barrier Models Are Urgently Needed for Modern Therapeutic Advances

by Karen O'Hanlon Cohrt | Feb 19, 2023 | Trends

Welcome to Part 4 of our series about the blood brain barrier (BBB)! Here, we highlight the rising global burden of neurological disorders, and recap on the challenges surrounding drug safety and toxicity in relation to the BBB. As industry speeds ahead with novel...

Sources of cells for modeling the human BBB — 4 considerations

by Karen O'Hanlon Cohrt | Jan 26, 2023 | Trends

Welcome to Part 3 of our blog series covering the blood brain barrier (BBB). In Part 1, we looked briefly at how the BBB was discovered and presented what we currently know about its composition and functions. Part 2 focused on the need for reliable BBB models in drug...

In Vitro Blood Brain Barrier Models for Drug Development

by Karen O'Hanlon Cohrt | Dec 18, 2022 | Trends

Welcome back to our blog series about the blood brain barrier (BBB). In Part 1, we provided a brief history on the discovery of the BBB, and introduced what we currently know about its composition and biological functions. In Part 2, we explain why reliable BBB models...